Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology

[1]  John C. Morris,et al.  AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure , 2017, NeuroImage.

[2]  Reisa A. Sperling,et al.  The association between tau PET and retrospective cortical thinning in clinically normal elderly , 2017, NeuroImage.

[3]  Henrik Zetterberg,et al.  18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease , 2017, EMBO molecular medicine.

[4]  Yi Su,et al.  Tau-PET Binding Distinguishes Patients With Early-stage Posterior Cortical Atrophy From Amnestic Alzheimer Disease Dementia , 2017, Alzheimer disease and associated disorders.

[5]  Keith A. Johnson,et al.  Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease , 2017, JAMA neurology.

[6]  Brian A. Gordon,et al.  Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. , 2016, JAMA neurology.

[7]  A. Fagan,et al.  Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy. , 2016, JAMA neurology.

[8]  Chengjie Xiong,et al.  Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease , 2016, Annals of neurology.

[9]  Keith A. Johnson,et al.  Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly , 2016, Neurology.

[10]  Yi Su,et al.  The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. , 2016, Brain : a journal of neurology.

[11]  Gereon R. Fink,et al.  Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease , 2016, Annals of clinical and translational neurology.

[12]  Hanna Cho,et al.  Tau PET in Alzheimer disease and mild cognitive impairment , 2016, Neurology.

[13]  Clifford R. Jack,et al.  An autoradiographic evaluation of AV-1451 Tau PET in dementia , 2016, Acta Neuropathologica Communications.

[14]  Yi Su,et al.  Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease , 2016, Science Translational Medicine.

[15]  Daniel R. Schonhaut,et al.  Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. , 2016, Brain : a journal of neurology.

[16]  A. Joshi,et al.  Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. , 2016, Brain : a journal of neurology.

[17]  G. Rabinovici,et al.  Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation. , 2016, Journal of Alzheimer's disease : JAD.

[18]  Daniel R. Schonhaut,et al.  PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.

[19]  O. Hansson,et al.  Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography , 2016, Brain : a journal of neurology.

[20]  Jorge Sepulcre,et al.  Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.

[21]  Keith A. Johnson,et al.  Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.

[22]  Abraham Z. Snyder,et al.  Quantitative Amyloid Imaging Using Image-Derived Arterial Input Function , 2015, PloS one.

[23]  Jingxia Liu,et al.  Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease , 2015, Neurology.

[24]  Sterling C. Johnson,et al.  Subjective memory complaints, cortical thinning, and cognitive dysfunction in middle-age adults at risk of AD , 2015, Alzheimer's & dementia.

[25]  John Seibyl,et al.  Improved longitudinal [18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction , 2015, NeuroImage.

[26]  Andrei G. Vlassenko,et al.  Quantitative Analysis of PiB-PET with FreeSurfer ROIs , 2013, PloS one.

[27]  Jorge L. Bernal-Rusiel,et al.  Spatiotemporal linear mixed effects modeling for the mass-univariate analysis of longitudinal neuroimage data , 2013, NeuroImage.

[28]  H. Kolb,et al.  [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease , 2013, Alzheimer's & Dementia.

[29]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[30]  Mert R. Sabuncu,et al.  Statistical analysis of longitudinal neuroimage data with Linear Mixed Effects models , 2013, NeuroImage.

[31]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[32]  Bruce Fischl,et al.  Within-subject template estimation for unbiased longitudinal image analysis , 2012, NeuroImage.

[33]  P. Scheltens,et al.  Atrophy of medial temporal lobes on MRI in “probable” Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[34]  C. Rowe,et al.  Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition , 2012, Neurology.

[35]  M. Weiner,et al.  The dynamics of cortical and hippocampal atrophy in Alzheimer disease. , 2011, Archives of neurology.

[36]  R. Killiany,et al.  Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults , 2011, Neurology.

[37]  C. Rowe,et al.  Relationship between atrophy and β‐amyloid deposition in Alzheimer disease , 2010, Annals of neurology.

[38]  B. Dickerson,et al.  The cortical signature of prodromal AD , 2009, Neurology.

[39]  R. Buckner,et al.  The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals , 2008, Cerebral cortex.

[40]  R. Mayeux,et al.  Hippocampal and entorhinal atrophy in mild cognitive impairment , 2007, Neurology.

[41]  Paul Edison,et al.  Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C‐PIB positron emission tomography study , 2006, Annals of neurology.

[42]  Kiralee M. Hayashi,et al.  Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. , 2006, Archives of neurology.

[43]  Nick C. Fox,et al.  Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease , 2004, NeuroImage.

[44]  J. Baron,et al.  In Vivo Mapping of Gray Matter Loss with Voxel-Based Morphometry in Mild Alzheimer's Disease , 2001, NeuroImage.

[45]  A M Dale,et al.  Measuring the thickness of the human cerebral cortex from magnetic resonance images. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[46]  A. Evans,et al.  Correction for partial volume effects in PET: principle and validation. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[47]  C. Jack,et al.  Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease , 1997, Neurology.

[48]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[49]  Philip S. Insel,et al.  F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer’s disease , 2017 .

[50]  Christopher J. Owen,et al.  Tau and Ab imaging, CSF measures, and cognition in Alzheimer’s disease , 2016 .

[51]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. , 2014, Journal of Alzheimer's disease : JAD.

[52]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. , 2013, Journal of Alzheimer's disease : JAD.